Press Release
July 16, 2019

Beta Bionics Announces Closing of a $63 Million Series B2 Financing

Professionals

The Life Sciences team advised Beta Bionics, a medical technology company leveraging lifelong autonomous learning to develop and commercialize the world’s first fully automated bionic pancreas, on a $63 million Series B2 equity financing. This follows six months after the final close of another $63 million equity financing and brings the total combined Series B and B2 financings to just over $126 million.

The Series B2 financing round was co-led by new investors Perceptive Advisors and Soleus Capital Management. In addition, Farallon Capital joined the round as a new investor in Beta Bionics. Series B lead investor, Eventide, together with RTW and ArrowMark, all participated in the Series B2 round. Beta Bionics will use the proceeds from these financings to complete final product development, phase 3 clinical trials, regulatory submissions, and product launch of the iLet Bionic Pancreas System.

Beta Bionics is a for-profit Massachusetts public benefit corporation founded in 2015 to commercialize the iLet, a revolutionary bionic pancreas that is driven by mathematical dosing algorithms, which incorporate lifelong machine-learning, and artificial intelligence to autonomously control glycemia.

The Goodwin team included partners Rob Puopolo, and law clerk Isabel Klosterman.

For more details, please read Bio Bionic’s press release.